Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor

• Published in: The oncologist (Dayton, Ohio) Vol. 20; no. 6; pp. 660 - 673
• Main Authors: Zhao, Yujie, Adjei, Alex A.
• Format: Journal Article
• Language: English
• Published: Durham, NC, USA AlphaMed Press 01.06.2015
• Subjects: Angiogenesis inhibitors; Angiogenesis Inhibitors - therapeutic use; Antibodies, monoclonal, humanized; Fibroblast growth factor; Fibroblast Growth Factors - genetics; Fibroblast Growth Factors - metabolism; Humans; Molecular Targeted Therapy; Neoplasms - drug therapy; Neoplasms - genetics; Neoplasms - pathology; Neovascularization, Pathologic - drug therapy; Neovascularization, Pathologic - genetics; Neovascularization, Pathologic - pathology; New Drug Development and Clinical Pharmacology; Platelet-Derived Growth Factor - genetics; Platelet-Derived Growth Factor - metabolism; Platelet‐derived growth factor; Receptors; Signal Transduction - drug effects; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - genetics; Vascular Endothelial Growth Factor A - metabolism; Vascular Endothelial Growth Factor Receptor-1 - genetics; Vascular Endothelial Growth Factor Receptor-1 - metabolism; Fibroblast growth factor; Molecular targeted therapy; Receptors; Platelet-derived growth factor; Antibodies, monoclonal, humanized; Angiogenesis inhibitors; Vascular endothelial growth factor

Angiogenesis, or the formation of new capillary blood vessels, occurs primarily during human development and reproduction; however, aberrant regulation of angiogenesis is also a fundamental process found in several pathologic conditions, including cancer. As a process required for invasion and metas...